Skip to main content

Arm CEO: AI Could Cure Cancer, But Chip Shortage Stands in the Way

Arm CEO Rene Haas has a bold vision: artificial intelligence could help humanity conquer cancer within our lifetime. But before we get there, he says, the industry must first solve a more down-to-earth problem—producing enough chips to power all that AI.

"I've always believed that the truly disruptive applications of AI are in healthcare," Haas said in a BBC interview released Tuesday. "AI can not only shorten the time required for drug development but also the time needed for drug testing."

"First, we need more wafer fabrication plants"

Haas, who joined Arm in 2013 and became CEO in February 2022 after seven years at NVIDIA, is no stranger to the tech world. In the interview, he expressed confidence that AI could tackle problems that have long stumped humans. "I believe that AI will help humanity cure cancer during our lifetime," he said.

But that ambition hinges on enormous computing power. And right now, the chips needed for cancer research and humanoid robots are being snapped up by AI companies planning massive data centers. "Currently, computing power supply is indeed very limited," Haas admitted. "Before we can build data centers in space, we first need more wafer fabrication plants—and I can tell you that clearly."

The demand for chips and memory from AI is unprecedented, Haas said. Building new fabrication plants isn't a quick fix either—each one can cost hundreds of billions of dollars and take two to three years to complete. The semiconductor industry, he noted, is in an "absolute environment of supply constraints," and the shortage will persist for some time.

Curing cancer isn't just about computing power

Even if the chip bottleneck were resolved tomorrow, it wouldn't guarantee a cancer cure in the next few years. Medical researchers are quick to point out that cancer isn't a single disease but a collection of more than 100 different conditions, each with its own complexities. AI can help identify potential drug targets and predict how drugs might behave, but its real-world impact on clinical medicine remains limited. The human body is full of variables that make it hard for models to reliably predict whether a candidate drug will work.

Other chip executives have echoed Haas's concerns. Manish Bhatia, COO of Micron, said in January that the current memory shortage is "indeed unprecedented," with HBM consuming so much capacity that traditional products like phones and PCs are facing "significant supply shortages." Qualcomm CEO Cristiano Amon noted in a February earnings call that "the memory shortage and price increases across the industry" will shape the smartphone market this year.

Data center expansion stirs local opposition

Meanwhile, the rapid growth of data centers in the U.S. is raising eyebrows. By the end of last year, more than 1,400 data centers had been completed or approved for construction. As they pop up in communities, concerns about air quality and water usage have grown. A Gallup poll in May found that 70% of American adults oppose building AI data centers in their local areas, with nearly half expressing "strong opposition."

So while the promise of AI-driven medical breakthroughs is exciting, the path forward is anything but smooth. From chip shortages to community pushback, there's plenty to figure out before we can truly say AI has cured cancer.

Key Points:

  • Arm CEO Rene Haas believes AI could help cure cancer within our lifetime.
  • The biggest bottleneck is the chip supply shortage, which requires more wafer fabrication plants.
  • Medical experts caution that cancer is complex and AI's clinical impact is still limited.
  • Other chip executives, like Micron's and Qualcomm's, also warn of unprecedented shortages.
  • Data center expansion is facing local opposition due to environmental concerns.